Healthcare
Supernus Pharmaceuticals, Inc.(SUPN)
Live Price
Offline$44.38
+1.84% today
1Y Change
+35.01%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- $2.76B
- Revenue Growth
- +8.6%
- EPS Growth
- -150.7%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Supernus Pharmaceuticals, Inc. (SUPN) is a Healthcare stock with a market cap of $2.76B and listed on NASDAQ. The stock last traded around $44.38 and up 35.0% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +8.6%, EPS growth of -150.7%, a dividend yield of 0.0%. What stands out right now is revenue +8.6%, EPS -150.7%, free cash flow -73.1% with operating margin -6.2% and ROIC -3.1%. Valuation is more restrained than many high-expectation growth names at price/sales 3.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SUPN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+8.6% vs +7.6% peer median
Operating Margin
Below sector median
-6.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +8.6% and EPS is at -150.7%, with operating margin around -6.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +4.6% | +2.7% | -10.5% |
2026 Feb 24, 2026 | +228.6% | +5.7% | +2.4% | -7.4% |
2025 Nov 4, 2025 | +23.2% | -17.4% | -19.1% | -21.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SUPN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SUPN Max Drawdown
-23.54%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SUPN and SPY.
Company Overview
Supernus Pharmaceuticals, Inc.
NASDAQ Global Market
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
- Leadership
- Jack A. Khattar
- IPO Date
- May 1, 2012
- Employees
- 674
- Street Address
- 9715 Key West Avenue
- Mailing
- Rockville, MD, 20850
- Region
- Rockville, MD, US
- Reporting Currency
- USD
- Investor Line
- 301 838 2500
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 25.4
- Price/Sales
- 3.8
- Price/Book
- 2.6
Growth
- Revenue
- +8.6%
- EPS
- -150.7%
- Free Cash Flow
- -73.1%
Profitability
- Gross Margin
- 85.5%
- Operating Margin
- -6.2%
- Net Margin
- -5.4%
- ROE
- -3.7%
- ROIC
- -3.1%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 1.90
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.